Who is sponsoring NCT00060502?

NCT00060502 is sponsored by Centocor, Inc..

What condition does NCT00060502 study?

NCT00060502 studies Cachexia, Pancreatic Neoplasms.

What drugs are being tested in NCT00060502?

Interventions: Infliximab; Gemcitabine.

What is the status of NCT00060502?

NCT00060502 is currently COMPLETED.

Last reviewed 2011-05-16 · How we verify

A Phase II, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Anti-TNF a Monoclonal Antibody (Infliximab) to Treat Cancer-Related Cachexia in Subjects With Pancreatic Cancer.

NCT00060502 Phase 2 COMPLETED

The purpose of this study is to evaluate the effectiveness and safety of infliximab, the active ingredient in Remicade, for the treatment of cachexia in pancreatic cancer patients who are receiving chemotherapy with gemcitabine.

Details

Lead sponsor	Centocor, Inc.
Phase	Phase 2
Status	COMPLETED
Enrolment	73
Start date	2003-04
Completion	2006-02

Conditions

Cachexia
Pancreatic Neoplasms

Interventions

Infliximab; Gemcitabine

Primary outcomes

Change in Lean Body Mass (LBM) from baseline to the end of first cycle, as measured by bioelectrical impedance analysis (BIA).